LivaNova
LIVN
75.93
+1.00
+1.33%
LivaNova
US · LIVN
#2263 by market cap
Listed 1970
75.93
+1.00
+1.33%
Live - 5344 symbols - heartbeat 20s ago
· 2026-10-08 02:49
After-hours
75.93
0.00%
Overnight
75.93
0.00%
- Market cap
- 4.18B
- P/E (TTM)i
- 22.40
- P/Bi
- 3.16
- EPSi
- -4.45
- Div yieldi
- 0.00%
- 52W posi
- 73%
Reader sentiment
Are you bullish or bearish on LIVN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.09, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +10.74% YoY
Margins
- Gross margin
- 67.71%
- Operating margin
- 14.36%
- Net margin
- -17.47%
Key ratios & quality
- Enterprise valuei
- 3.93B
- Altman Z-Scorei
- 2.09
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.11B | 1.08B | 934.24M | 1.04B | 1.02B | 1.15B | 1.25B | 1.39B |
| Gross profit | 734.96M | 723.81M | 594.76M | 705.99M | 707.23M | 755.82M | 853.48M | 939.87M |
| Selling & admin expenses | 464.97M | 528.47M | 446.56M | 471.90M | 469.24M | 502.70M | 508.88M | 548.81M |
| Research & development | 145.95M | 146.85M | 152.90M | 183.41M | 155.81M | 193.82M | 182.51M | 185.76M |
| Operating profit | 86.85M | 13.38M | -72.47M | -784.00K | 52.64M | 21.48M | 129.05M | 199.39M |
| Pretax profit | -247.45M | -188.38M | -348.02M | -124.47M | -75.14M | -81.23M | 88.31M | -220.78M |
| Tax | -69.63M | -30.37M | -960.00K | 11.20M | 11.05M | -98.88M | 25.06M | 21.64M |
| Net profit | -189.40M | -157.64M | -348.82M | -135.82M | -86.25M | 17.55M | 63.23M | -242.47M |
| Basic EPS | -4 | -3 | -7 | -3 | -2 | 0 | 1 | -4 |
| Diluted EPS | -3.91 | -3.26 | -7.18 | -2.68 | -1.61 | 0.32 | 1.16 | -4.45 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 316.86M | 352.52M | 357.75M | 360.92M | 362.26M | 390.59M |
| Gross profit | 216.25M | 238.99M | 244.86M | 239.77M | 243.75M | 273.67M |
| Selling & admin expenses | 129.15M | 137.78M | 138.52M | 143.37M | 143.57M | 158.13M |
| Research & development | 37.88M | 47.19M | 48.58M | 52.12M | 58.70M | 53.66M |
| Operating profit | 48.62M | 54.18M | 54.01M | 42.58M | 41.47M | 49.48M |
| Pretax profit | -315.65M | 33.32M | 33.91M | 27.63M | 27.49M | 18.48M |
| Tax | 11.66M | 6.15M | 7.11M | -3.28M | 4.34M | -90.20M |
| Net profit | -327.32M | 27.16M | 26.78M | 30.91M | 22.29M | 108.57M |
| Basic EPS | -6 | 1 | 0 | 1 | 0 | 2 |
| Diluted EPS | -6.01 | 0.50 | 0.49 | 0.56 | 0.40 | 1.93 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 533.30M | 549.44M | 708.04M | 679.18M | 886.14M | 988.16M | 1.13B | 1.10B |
| Cash & ST investments | 47.20M | 61.14M | 252.83M | 207.99M | 214.17M | 266.50M | 428.86M | 635.55M |
| Inventory | 153.54M | 164.15M | 115.29M | 105.84M | 129.38M | 147.89M | 147.57M | 164.70M |
| Total assets | 2.55B | 2.41B | 2.40B | 2.20B | 2.29B | 2.43B | 2.51B | 2.61B |
| Total current liabilities | 496.75M | 512.55M | 309.05M | 696.97M | 297.40M | 334.98M | 392.13M | 808.07M |
| Short-term debt | 28.79M | 88.51M | 24.62M | 240.93M | 32.81M | 26.47M | 87.04M | 40.26M |
| Long-term debt | 139.54M | 260.33M | 642.30M | 9.85M | 518.07M | 568.54M | 549.62M | 345.19M |
| Total liabilities | 1,045,963,000.00 | 1,028,080,000.00 | 1,290,696,000.00 | 906,306,000.00 | 1,087,149,000.00 | 1,151,935,000.00 | 1,186,131,000.00 | 1,406,066,000.00 |
| Total equity | 1.50B | 1.38B | 1.11B | 1.29B | 1.21B | 1.28B | 1.32B | 1.20B |
| Retained earnings | -251.58M | -406.76M | -761.97M | -897.78M | -984.03M | -966.48M | -903.25M | -1.15B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.17B | 1.07B | 1.10B | 1.10B | 1.01B | 1.03B |
| Cash & ST investments | 738.44M | 593.64M | 646.08M | 635.55M | 539.71M | 516.62M |
| Inventory | 154.02M | 165.35M | 167.54M | 164.70M | 165.50M | 172.61M |
| Total assets | 2.56B | 2.51B | 2.56B | 2.61B | 2.52B | 2.64B |
| Total current liabilities | 741.57M | 827.10M | 827.59M | 808.07M | 762.48M | 707.00M |
| Short-term debt | 88.30M | 91.51M | 94.44M | 40.26M | 11.59M | 12.37M |
| Long-term debt | 549.22M | 348.49M | 349.03M | 345.19M | 285.16M | 289.91M |
| Total liabilities | 1,524,448,000.00 | 1,383,863,000.00 | 1,400,353,000.00 | 1,406,066,000.00 | 1,305,025,000.00 | 1,315,539,000.00 |
| Total equity | 1.03B | 1.12B | 1.16B | 1.20B | 1.21B | 1.33B |
| Retained earnings | -1.23B | -1.20B | -1.18B | -1.15B | -1.12B | -1.01B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 120.49M | -91.14M | -79.42M | 102.54M | 69.92M | 74.91M | 183.04M | 254.34M |
| Depreciation & amortization | 69.94M | 82.99M | 81.32M | 67.99M | 57.80M | 60.86M | 51.14M | 59.63M |
| Free cash flow | 82.49M | -115.83M | -114.45M | 77.07M | 43.40M | 39.93M | 135.93M | 173.29M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -50.00M | 0 | 0 | 322.56M | -- | -- | -- | -- |
| Ending cash balance | 47.20M | 61.14M | 252.83M | 207.99M | 515.62M | 577.87M | 723.56M | 635.55M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 23.97M | 62.92M | 85.06M | 82.40M | 15.22M | 66.59M |
| Depreciation & amortization | 14.67M | 15.04M | 15.22M | 14.71M | 15.60M | 18.20M |
| Free cash flow | 13.18M | 47.77M | 62.18M | 50.16M | 926.00K | 35.04M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 738.44M | 593.64M | 646.08M | 635.55M | 539.71M | 516.62M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -11.41 | -10.75 | -27.57 | -11.26 | -6.89 | 1.41 | 4.87 | -19.24 |
| ROA %i | -7.50 | -6.26 | -14.31 | -5.89 | -3.84 | 0.74 | 2.56 | -9.49 |
| ROIC %i | -10.07 | -8.30 | -16.88 | -5.84 | -3.08 | 2.52 | 4.44 | -12.04 |
| 5-year avg ROE %i | -- | -- | -11.06 | -12.61 | -13.70 | -11.14 | -7.98 | -6.23 |
| EBIT margin %i | -21.47 | -15.74 | -32.45 | -7.18 | -2.63 | -1.94 | 12.08 | -12.36 |
| FCF / sales %i | 7.45 | -- | -- | 7.44 | 4.25 | 3.46 | 10.84 | 12.48 |
| Current ratioi | 1.07 | 1.07 | 2.29 | 0.97 | 2.98 | 2.95 | 2.87 | 1.36 |
| Quick ratioi | 0.70 | 0.70 | 1.61 | 0.62 | 1.44 | 1.50 | 1.66 | 1.11 |
| Debt / assetsi | 6.60 | 16.37 | 29.55 | 13.03 | 25.29 | 26.36 | 27.00 | 16.64 |
| LT debt / equityi | 9.28 | 22.14 | 61.71 | 3.54 | 45.35 | 48.05 | 44.67 | 32.79 |
| Interest coveragei | -24.19 | -11.30 | -7.42 | -1.48 | -0.56 | -0.38 | 2.40 | -3.48 |
| Revenue CAGR (3Y) %i | -- | 3.96 | -2.64 | -2.20 | -1.96 | 7.28 | 6.58 | 10.75 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -2.24 | -- | -- | 20.82 | 58.64 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -19.70 | -17.87 | -17.63 | -19.24 | 9.54 | 15.40 |
| ROA %i | -8.85 | -8.52 | -8.56 | -9.49 | 4.22 | 7.33 |
| ROIC %i | -10.86 | -10.51 | -10.62 | -12.04 | 7.98 | 12.17 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -10.25 | -9.33 | -10.21 | -12.36 | 11.49 | 9.65 |
| FCF / sales %i | 11.41 | 12.38 | 14.19 | 12.48 | 11.23 | 10.08 |
| Current ratioi | 1.58 | 1.29 | 1.33 | 1.36 | 1.33 | 1.45 |
| Quick ratioi | 1.31 | 1.02 | 1.07 | 1.11 | 1.06 | 1.12 |
| Debt / assetsi | 26.49 | 19.26 | 19.02 | 16.64 | 13.65 | 13.33 |
| LT debt / equityi | 57.00 | 34.85 | 33.88 | 32.79 | 27.40 | 25.62 |
| Interest coveragei | -2.09 | -2.06 | -2.54 | -3.48 | 3.89 | 4.11 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Cardiopulmonary is the largest reported line at 56.73% of revenue, across 3 reported segments.
- Neuromodulation follows at 42.74%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Cardiopulmonary56.73%
Neuromodulation42.74%
Other revenue0.53%
Quote time 2026-10-08 02:49:39 · For reference only, not investment advice and not tailored to your situation.